Realizing the Goals of the Advancing American Kidney Health Initiative: Toward a Better Future for Kidney Disease Research Funding

  • Ryan Murray
    Address correspondence to Ryan Murray, BA, American Society of Nephrology, 1401 H Street NW, Suite 900, Washington, DC 20005.
    American Society of Nephrology, Washington, DC

    Division of Nephrology and Hypertension, Departments of Public Health Sciences and Medicine, Loyola University Chicago, Maywood, IL
    Search for articles by this author
  • Holly Kramer
    American Society of Nephrology, Washington, DC

    Division of Nephrology and Hypertension, Departments of Public Health Sciences and Medicine, Loyola University Chicago, Maywood, IL
    Search for articles by this author
      The Executive Order on Advancing American Kidney Health aimed to slow the progression of kidney disease, increase access to kidney transplantation, and expand home dialysis. In order to support the kidney health strategy laid out by the Advancing American Kidney Health, the National Institutes of Health, the National Institute of Diabetes, and Digestive, and Kidney Diseases, as well as other funding agencies must dedicate robust research funding to kidney disease. Currently, federal research investment for kidney health is less than 1% of Medicare fee-for-service expenditures for Americans with kidney disease. To address disparities in federal research funding, nephrology organizations are working together to advocate for increased federal commitment to kidney disease research. Underfunding of kidney disease research impedes scientific opportunities and innovation and prevents the collaboration of young investigators with research faculty that can accelerate the exodus of talent within the nephrology research workforce. This review provides an overview of the current state of federal research funding for kidney disease within the United States. In addition, we discuss ongoing advocacy efforts and programs that aim to increase federal funding for kidney-related research and accelerate the development of new and better therapies.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Centers for Disease Control and Prevention
        Chronic kidney disease in the United States, 2021.
        US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA2021
        • Johansen K.L.
        • Chertow G.M.
        • Foley R.N.
        • et al.
        US renal data system 2020 annual data report: epidemiology of kidney disease in the United States.
        Am J Kidney Dis. 2021; 77: A7-A8
        • McCullough K.P.
        • Morgenstern H.
        • Saran R.
        • Herman W.H.
        • Robinson B.M.
        Projecting ESRD incidence and prevalence in the United States through 2030.
        J Am Soc Nephrol. 2019; 30: 127-135
        • Rettig R.A.
        Originas of the medicare kidney disease entitlement: the Social Security Amendment of 1972.
        in: Hanna K.E. Biomedical Politics. National Academies Press (U.S.), Washington, DC1991: 176-182
        • Murray R.
        • Zimmerman T.
        • Agarwal A.
        • et al.
        Kidney-related research in the United States: a position statement from the national kidney foundation and the American Society of Nephrology.
        Am J Kidney Dis. 2021; 78: 161-167
      1. H.R. 34-21st century cures act. H.R. 34-114th congress 2015-2016.
        (Accessed October 15, 2021)
        • Abdel-Kader K.
        • Unruh M.L.
        • Weisbord S.D.
        Symptom burden, depression, and quality of life in chronic and end-stage kidney disease.
        Clin J Am Soc Nephrol. 2009; 4: 1057-1064
        • National Kidney Foundation Research Roundtable Work Group on behalf of the National Kidney Foundation
        Research priorities for kidney-related research-an agenda to advance kidney care: a position statement from the national kidney foundation.
        Am J Kidney Dis. 2021; 79: 141-152
        • Ketchum C.
        A path forward for kidney research. Joint ASN-NIDDK Webinar: perspective on the state of NIDDK kidney research and workforce pipeline.
        (Accessed May 7, 2021)
        • Delgado C.
        • Baweja M.
        • Crews D.C.
        • et al.
        A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease.
        Am J Kidney Dis. 2021; 79: 268-288
        • Inker L.A.
        • Eneanya N.D.
        • Coresh J.
        • et al.
        New creatinine- and cystatin C-based equations to estimate GFR without race.
        N Engl J Med. 2021; 385: 1737-1749
        • U.S. Department of Health and Human Services
        The national institute of diabetes, digestive and kidney disease. National Kidney Disease Education Program.
        (Accessed October 15, 2021)
        • Centers for Disease Control and Prevention
        Chronic Kidney Disease Surveillance System—United states.
        2021 (Accessed October 19, 2021)
      2. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm hg.
        JAMA. 1967; 202: 1028-1034
        • Veterans Administration Cooperative Study Group on Antihypertensive Agents
        Effects of treatment on morbidity in hypertension. III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.
        Circulation. 1972; 45: 991-1004
        • Roccella E.J.
        • Ward G.W.
        The national high blood pressure education program: a description of its utility as a generic program model.
        Health Educ Q. 1984; 11: 225-242
        • Mensah G.A.
        • Kiley J.
        • Mockrin S.C.
        • et al.
        National heart, lung, and blood institute strategic visioning: setting an agenda together for the NHLBI of 2025.
        Am J Public Health. 2015; 105: e25-e28
        • Mensah G.A.
        • Wei G.S.
        • Sorlie P.D.
        • et al.
        Decline in cardiovascular mortality: possible causes and implications.
        Circ Res. 2017; 120: 366-380
        • GBD Chronic Kidney Disease Collaboration
        Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017.
        Lancet. 2020; 395: 709-733
      3. American Association of Medical Colleges. Accessed August 20, 2021.

        • National Kidney Foundation Patient Registry
        (Updated 2021.) (Accessed October 21, 2021.)